Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00889161 · ClinicalTrials.gov registry record · Phase 1
Curcumin in Pediatric Inflammatory Bowel Disease
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00889161 is a Phase 1 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 11 participants.
The verdict
NCT00889161, a Phase 1 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a single center, open label forced dose titration study designed to determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease (IBD). This study will provide initial tolerability and safety data in pediatric patients with IBD. Twenty patients with IBD in remission or with mild disease (score \<34 on PUCAI or score \<30 on the PCDAI) on sulfasalazine or mesalamine aged 8 to 18 years will be enrolled into this study. Each patient will participate in the study for nine weeks. From this study an appropriate dosage will be determined to proceed with a double blinded placebo controlled study.
Interventions
- DRUG Curcumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00889161
The ClinicalTrials.gov registry entry for NCT00889161 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Curcumin is the first listed.
NCT00889161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00889161 about?
NCT00889161 is a clinical study titled "Curcumin in Pediatric Inflammatory Bowel Disease". This is a single center, open label forced dose titration study designed to determine the tolerability of curcumin in pediatric patients with inflammatory bowel disease (IBD). This study will provide initial tolerability and safety data in pediatric patients with IBD. Twenty patients with IBD in rem...
What is the current status of trial NCT00889161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2009-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00889161?
The interventions under investigation include: Curcumin (DRUG).
Who is sponsoring clinical trial NCT00889161?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.